QBS-10072S is under clinical development by Quadriga BioSciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QBS-10072S’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QBS-10072S is under development for the treatment of solid tumors including bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colorectal cancer, esophageal cancer, gastric cancer, triple negative breast cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, malignant pleural mesothelioma, prostate cancer, sarcoma, tongue cancer, thymic carcinoma, urinary tract cancer, brain tumor like glioblastoma multiforme and multiple myleoma. The drug candidates constitute cytotoxic moiety chemically fused to a LAT1 specific recognition element. The drug candidate acts by targeting large amino acid transporter 1 (LAT1). It is administered through intravenous route.
Quadriga BioSciences overview
Quadriga BioSciences is an oncology start-up focused on developing targeted anti-cancer drugs. Quadriga BioSciences is headquartered in Los Altos, California, the US.
For a complete picture of QBS-10072S’s drug-specific PTSR and LoA scores, buy the report here.